-

Bruker Light-Sheet Microscopes at Major Comprehensive Cancer Center

New Advanced Imaging Center Powered by Two MuVi and LCS SPIM Microscopes

NEW YORK--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR), a leading supplier of single-plane illumination microscopy (SPIM) technology for research on live cells and cleared biological samples, today announced that two Luxendo MuVi™ and LCS SPIM™ light-sheet microscopes have been installed by Memorial Sloan Kettering Cancer Center (MSK). The funding for the two light-sheet fluorescence microscopes was supported by Cycle for Survival (https://www.cycleforsurvival.org). The new SPIM microscopes will help researchers visualize the cellular and tissue hallmarks of cancer and translate those findings into better cancer treatment methods.

“By understanding how cells mobilize to build organs, researchers can glean insights into why some cells become cancerous and lead to organ destruction,” said Dr. Anna-Katerina Hadjantonakis, MSK Chair of the Developmental Biology Program. “Instruments such as these are useful for imaging across differing length scales — from subcellular to single cells to tissue-level processes — allowing researchers to study cellular dynamics and cellular motion, processes that enable cells to metastasize.”

“Light-sheet fluorescence microscopy has emerged as a uniquely powerful method for high-resolution, cleared-sample and dynamic biological imaging,” added Dr. Lars Hufnagel, Vice President and General Manager of Bruker’s Luxendo light-sheet microscopy business. “We couldn’t be more pleased that our technology will be assisting the great MSK researchers and programs in such important work.”

About the MuVi and LCS SPIM Systems
Bruker’s SPIM systems avoid sample phototoxicity by sequentially illuminating a stack of small slices of the organism, allowing scientists to observe living organisms for extended periods of time without photodamage. In particular, MuVi SPIM allows fast 3D imaging of live cells and living objects, such as spheroids and whole specimens, without the need of sample rotation. Despite the fact that sample rotation is not necessarily needed for a non-isotropic acquisition, the MuVi SPIM system provides this degree of freedom such that isotropic resolution can be achieved.

The modular LCS SPIM for large, cleared samples has been designed to be compatible with a broad variety of clearing solutions and sample sizes. Its new sample mounting approach and innovative optical design enables unprecedented acquisition times and minimizes sample distortions while seamlessly integrating into existing clearing and sample preparation pipelines. To handle the vast amount of data produced by the light-sheet technique, Lux DATA comprehensive data processing and storage provides fast transfer and large-capacity storage and leverages multi-core- and multi-GPU-based processing.

About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

Contacts

Investor Contact:
Miroslava Minkova
Director of Investor Relations & Corporate Development
T: +1 (978) 663-3660, ext. 1479
E: Investor.Relations@bruker.com

Media Contact:
Stephen Hopkins
Content Marketing Manager
Bruker Nano Fluorescence Microscopy
T: +1 (520) 741-1044 x1022
E: steve.hopkins@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Summary
Bruker Light-Sheet Microscopes at Major Comprehensive Cancer Center
Release Versions

Contacts

Investor Contact:
Miroslava Minkova
Director of Investor Relations & Corporate Development
T: +1 (978) 663-3660, ext. 1479
E: Investor.Relations@bruker.com

Media Contact:
Stephen Hopkins
Content Marketing Manager
Bruker Nano Fluorescence Microscopy
T: +1 (520) 741-1044 x1022
E: steve.hopkins@bruker.com

More News From Bruker Corporation

Bruker Accelerates the Future of Diagnostic and Prognostic Spatial Proteomics with the Launch of CellScape XR

ORLANDO, Fla.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced the launch of CellScape™ XR, a next-generation spatial proteomics platform designed to advance the development of diagnostic and prognostic assays by delivering unprecedented quantitative performance, robustness, and flexibility. CellScape XR addresses a critical bottleneck in translational research by enabling high-throughput, reproducible spatial proteomics at a scale and rigor required for translational and clinical...

Bruker Expands Collaboration with Noetik to Advance Tissue Foundational Models for Translational and Therapeutic Applications

ORLANDO, Fla.--(BUSINESS WIRE)--Bruker Spatial Biology, a division of Bruker Corporation (Nasdaq: BRKR) announced today that it will expand its collaboration with Noetik Inc., following their prior study of more than 3500 patient samples with the CosMx® Spatial Molecular Imager (SMI). CosMx SMI powers Noetik's pre-training and scaling of bio-foundation models to perform complex genome-wide simulations of human cellular- and tissue-level biology to enable diverse therapeutics applications. “Noet...

Bruker Announces Major Advancements at AGBT to Enable Complete High-Fidelity Spatial Biology Across the Biological Spectrum

ORLANDO, Fla.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today significant portfolio advancements from Bruker Spatial Biology to be unveiled at the 2026 Advances in Genome Biology and Technology (AGBT) General Meeting. These updates highlight Bruker’s category leadership in spatial biology and its commitment to delivering best‑in‑class solutions across DNA, RNA, and protein. The Bruker Spatial Biology division will launch several new products, introduce expanded capabilities,...
Back to Newsroom